You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y., Feb 01, 2006 -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter international sales for its flagship product, Tarceva® (erlotinib). Net international sales...
Recently, new information was added to the US labeling for the class of topical calcineurin inhibitors, or TCIs, which includes Protopic® (tacrolimus) Ointment and pimecrolimus cream. The new...
MELVILLE, N.Y., Jan 11, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter and year-end net U.S. sales for its flagship product, Tarceva® (erlotinib)....
First arginine vasopressin (AVP) antagonist approved for the management of potentially lifethreatening sodium/water imbalance DEERFIELD, Illinois, December 30 — Astellas Pharma US, Inc. today...
Read more about FDA Approves Astellas' Vaprisol® for the Treatment of Euvolemic Hyponatremia
Follow U.S. news
